medigraphic.com
ISSN 1727-897X (Electronic)

2022, Number 4

<< Back Next >>

Medisur 2022; 20 (4)

Proposal for a predictive scale of cognitive impairment in adult patients with neurocysticercosis

Anaya GJL, López-Muñoz F, Carmona Alvarez-Builla E, Miniet CAE, Moreira TL

Language: Spanish
References: 28
Page: 28
PDF size: 412.27 Kb.


ABSTRACT

Background Cognitive impairment in patients with neurocysticercosis is frequent, therefore, it is very useful to have prognostic instruments to establish a better management of it.
Objective to propose a predictive scale of cognitive impairment in adult patients with neurocysticercosis.
Methods study with a correlational, prospective and cross-sectional design, which included 93 patients with neurocysticercosis. Through data provided by previous research, the variables were selected, which were related to the appearance of cognitive impairment in the bivariate analysis (p<0.05). As a multivariate analysis technique, a multidimensional scaling (PROXSCAL) was performed (s-stress < 0.001 and Tucker's congruence coefficient > 0.999). The prognostic performance of each of the variables was determined by means of sensitivity, specificity, and positive and negative predictive values, with their respective 9 5% confidence intervals.
Results a scale with a dichotomous format was developed, which included 7 factors (4 clinical and 3 tomographic), with which a score of 0 to 7 points was obtained for the prediction of cognitive impairment in adult patients with neurocysticercosis, with a probability of: 0-1 point: 75.3 %; 2-3 points: 95 %; ≥ 4 points: 96 %.
Conclusion The proposed instrument has an acceptable prognostic accuracy; it is simple, reproducible and requires little time for its application. Despite its limitations, it could improve the quality of care for patients with neurocysticercosis, since it allows guiding the management of this condition.


REFERENCES

  1. Bartoloni LC. Deterioro cognitivo. Diagnosis. 2019;(16):27-35.

  2. Ortiz JC. Procesos cognitivos en daño cerebral por infección. Psicoespacios[Internet]. 2019[citado 01/04/2022];13(22):[aprox. 40p]. Disponible en: https://revistas.iue.edu.co/index.php/Psicoespacios/article/view/1209/14462.

  3. García S, Díaz MC, Peraita H. Evaluación y seguimiento del envejecimiento sano y con deterioro cognitivo leve (DCL) a través del TAVEC. Anal Psicol[Internet]. 2014[citado 01/04/2022];30(1):[aprox. 11p]. Disponible en: https://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S0212-972820140001000403.

  4. Gómez I, Andrés EM, Gómez A, Peralta P. Análisis del efecto a largo plazo de un programa de estimulación cognitiva en mayores con deterioro cognitivo leve en Atención Primaria: ensayo controlado aleatorizado. Aten Primaria. 2021;53(7):102053.

  5. Raibagkar P, Berkowitz AL. The Many Faces of Neurocysticercosis. J Neurol Sci[Internet]. 2018;390:75-6.

  6. Guzman C, Garcia HH. Current Diagnostic Criteria for Neurocysticercosis. Res Rep Trop Med. 2021;12:197-203.

  7. Mukendi D, Kalo JRL, Lutumba P, Barbé B, Jacobs J, Yansouni CP, et al. High frequency of Taenia solium antigen positivity in patients admitted for neurological disorders in the Rural Hospital of Mosango, Democratic Republic of Congo. BMC Infect Dis. 2021;21(1):359.

  8. Garcia HH, Nash TE, del Brutto OH. Clinical symptoms, diagnosis, and treatment of neurocysticercosis. Lancet Neurol. 2014;13(12):1202-15.

  9. Garcia HH. Neurocysticercosis. Neurol Clin. 2018;36(4):851-64.

  10. Garcia HH, Gonzalez AE, Gilman RH. Taenia solium Cysticercosis and Its Impact in Neurological Disease. Clin Microbiol Rev. 2020;33(3):e00085-19.

  11. Aguilera OR, González D, Gómez F. Neurocisticercosis masiva. Presentación de un caso y revisión de la literatura. Rev Finlay[Internet]. 2021[citado 01/04/2022];11(1):[aprox. 7p]. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S2221-2434202100010008811.

  12. Sharma S, Modi M, Lal V, Prabhakar S, Bhardwaj A, Sehgal R. Reversible dementia as a presenting manifestation of racemose neurocysticercosis. Ann Indian Acad Neurol. 2013;16(1):88-90.

  13. Ramírez DT, Martella D. Limited protective effects of cognitive reserve on the progression of cognitive impairment. Revista Medica de Chile. 2019;147(12):1594-612.

  14. Anaya JL, López-Muñoz F, Carmona E, Miniet AE. Correlación entre estado cognitivo y hallazgos tomográficos en pacientes con neurocisticercosis. Ecuador, 2019 - 2020. Medisur[Internet]. 2022[citado 10/05/2022];20(3):[aprox. 10p]. Disponible en: http://www.medisur.sld.cu/index.php/medisur/article/view/5238/375714.

  15. del Brutto OH, Nash TE, White AC, Rajshekhar V, Wilkins PP, Singh G, et al. Revised diagnostic criteria for neurocysticercosis. J Neurol Sci. 2017;372:202-10.

  16. Escribano M, Pérez M, García FJ, Pérez A, Romero L, Ferrer G, et al. Validación del MMSE de Folstein en una población española de bajo nivel educativo1. Revista Española de Geriatría y Gerontología[Internet]. 1999[citado 01/04/2022];[aprox. 20p]. Disponible en: https://www.elsevier.es/es-revista-revista-espanola-geriatria-gerontologia-124-articulo-validacion-del-mmse-folstein-una-1301168516.

  17. de Beaman SR, Beaman PE, Garcia C, Villa MA, Heres J, Córdova A, et al. Validation of a Modified Version of the Mini-Mental State Examination (MMSE) in Spanish. Aging Neuropsychology and Cognition. 2004;11(1):1-11.

  18. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189-98.

  19. Arce C, de Francisco C, Arce I. Escalamiento multidimensional: concepto y aplicaciones multidimensional. Papeles del Psicólogo. 2010[citado 01/04/2022];31(1):[aprox. 22p]. Disponible en: https://www.papelesdelpsicologo.es/pdf/1795.pdf19.

  20. Nau AL, Mwape KE, Wiefek J, Schmidt K, Abatih E, Dorny P, et al. Cognitive impairment and quality of life of people with epilepsy and neurocysticercosis in Zambia. Epilepsy Behav. 2018;80:354-9.

  21. Ursini T, di Giacomo R, Caldrer S, Angheben A, Zammarchi L, Filipponi S, et al. Neurocysticercosis-related seizures in the post-partum period: two cases and a review of the literature. Lancet Infect Dis. 2020;20(8):e204-14.

  22. del Brutto OH, Mera RM, Wu S, Recalde BY, Issa NP. Epilepsy, interictal EEG abnormalities and hippocampal atrophy in patients with calcified neurocysticercosis: a population study in an endemic milieu. Epileptic Disord. 2021;23(2):357-65.

  23. Ciampi De Andrade D, Rodrigues CL, Abraham R, Castro LHM, Livramento JA, Machado LR, et al. Cognitive impairment and dementia in neurocysticercosis: a cross-sectional controlled study. Neurology. 2010;74(16):1288-95.

  24. Nash TE, O'Connell EM. Subarachnoid neurocysticercosis: emerging concepts and treatment. Curr Opin Infect Dis. 2020;33(5):339-46.

  25. Saini AG, Vyas S, Singhi P. Racemose neurocysticercosis. J Infect Public Health. 2017;10(6):884-5.

  26. Mahale RR, Mehta A, Rangasetty S. Extraparenchymal (Racemose) Neurocysticercosis and Its Multitude Manifestations: A Comprehensive Review. J Clin Neurol. 2015;11(3):203-11.

  27. Parra DM, Vargas MT, Montejo JA, Calderon CM, Severiche DF. Subarachnoid racemose neurocysticercosis with cerebellar involvement: an old friend in an infrequent location? Rev Inst Med Trop Sao Paulo. 2021;63:e43.

  28. Singhi P, Malhi P, Suthar R, Deo B, Khandelwal NK. Long-term Cognitive Outcome of Children With Parenchymal Neurocysticercosis: A Prospective Observation Study. J Child Neurol. 2018;33(7):468-73.




2020     |     www.medigraphic.com